FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308396211> ?p ?o ?g. }

• W4308396211 abstract "<h3>Background</h3> Epithelial OVCA remains a highly fatal disease. FSHR is a tissue specific antigen expressed in >55% of high-grade epithelial OVCAs of different histological types. No significant FSHR expression is found in non-ovarian healthy tissues in women (figure 1). The treatment of OVCA patient derived xenografts with FSHCER T (FSH-Chimeric Endocrine Receptor + T-Cell (CER T)) cells (figure 2) in controlled, paired, mice was shown to effectively redirect the cytotoxic activity of T cells against patient-derived FSHR+ ovarian carcinomas (figure 3).¹ We hypothesize targeting FSHR in women with FSHR+ OVCA will result in improved response rates due to engraftment, expansion, and survival of these adoptively transferred FSHCER T cells and will have acceptable toxicity. <h3>Methods</h3> This is an open phase 1 dose-escalation study (NCT05316129) in high-grade epithelial OVCA to assess the safety of autologous T cells genetically modified to express CER targeting FSHR. Primary objective is to assess the safety of the intraperitoneal (IP) and intravenous (IV) infusions of FSHCER T cells with or without prior cyclophosphamide plus fludarabine. Secondary objectives include antitumor efficacy, persistence of transferred FSHR T cells, expansion of endogenous tumor-targeted cells, and to compare IP and IV routes of administration., A screening part of the study will examine archived tissue from patients with recurrent platinum resistant or refractory OVCA following 2-8 prior lines of chemotherapy. Those who demonstrate positive or indeterminate FSHR Expression by an RNA Salah Targeted Expression Panel (STEP) will be eligible to screen for the treatment dose-escalation portion. Additional criteria include measurable or evaluable disease; performance status 0-2; adequate bone marrow, renal, and hepatic function; and eligibility for IP catheter placement. If a patient is unable to be treated in the IP arm, the patient may be treated in the IV arm in the lowest unfilled cohort for that arm. Cohorts of 3 to 6 patients will be infused with escalating doses of FSHCER T cells to establish the maximum tolerated dose (MTD) with 6 planned dose levels: 1 × 10⁵, 3 × 10⁵, 1 × 10⁶, 3 × 10⁶, and 1 x 10⁷ FSHCER T cells/kg. If the MTD is not established after 3 × 10⁶, then next cohorts will receive conditioning cytoxan/fludarabine 5 days before starting T-cell infusion at dose levels 1 × 10⁶, 3 × 10⁶ and 1 × 10⁷ FSHCER T cells/kg. Following determination of MTD, an expansion phase will be initiated. <h3>Acknowledgements</h3> We wish to acknowledge Carrie Thomas, Keri Erb, Tam Jackson, Allison Murphy, Van Barnes, Kumar Karyampudi, Samantha Demmi, Denise Dorman, Cheryl Cox, Tanner Pearson, Brook Olmo, and many others on the teams at both Moffitt Cancer Center and Anixa Biosciences involved in cell therapies and clinical trial development and execution who have helped to enable this study. <h3>Trial Registration</h3> NCT05316129 <h3>Reference</h3> Perales-Puchalt A, Svoronos N, Rutkowski MR, Allegrezza MJ, Tesone AJ, Payne KK, Conejo-Garcia JR. Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. <i>Clin Cancer Res.</i> 2017;<b>23</b>(2):441–453. doi:10.1158/1078-0432.CCR-16-0492 <h3>Ethics Approval</h3> This study was approved by Moffitt Scientific Review #21113 and Advarra Institutional Review Board #00000971. Patients give informed consent before participation." @default.
• W4308396211 created "2022-11-11" @default.
• W4308396211 creator A5024457228 @default.
• W4308396211 creator A5028956946 @default.
• W4308396211 creator A5040390930 @default.
• W4308396211 creator A5044655732 @default.
• W4308396211 creator A5060460614 @default.
• W4308396211 creator A5070388369 @default.
• W4308396211 creator A5076100445 @default.
• W4308396211 creator A5084138890 @default.
• W4308396211 creator A5090402620 @default.
• W4308396211 date "2022-11-01" @default.
• W4308396211 modified "2023-09-27" @default.
• W4308396211 title "672 Phase I clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer (OVCA)" @default.
• W4308396211 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0672" @default.
• W4308396211 hasPublicationYear "2022" @default.
• W4308396211 type Work @default.
• W4308396211 citedByCount "0" @default.
• W4308396211 crossrefType "proceedings-article" @default.
• W4308396211 hasAuthorship W4308396211A5024457228 @default.
• W4308396211 hasAuthorship W4308396211A5028956946 @default.
• W4308396211 hasAuthorship W4308396211A5040390930 @default.
• W4308396211 hasAuthorship W4308396211A5044655732 @default.
• W4308396211 hasAuthorship W4308396211A5060460614 @default.
• W4308396211 hasAuthorship W4308396211A5070388369 @default.
• W4308396211 hasAuthorship W4308396211A5076100445 @default.
• W4308396211 hasAuthorship W4308396211A5084138890 @default.
• W4308396211 hasAuthorship W4308396211A5090402620 @default.
• W4308396211 hasBestOaLocation W43083962111 @default.
• W4308396211 hasConcept C121608353 @default.
• W4308396211 hasConcept C126322002 @default.
• W4308396211 hasConcept C143998085 @default.
• W4308396211 hasConcept C147483822 @default.
• W4308396211 hasConcept C154317977 @default.
• W4308396211 hasConcept C202751555 @default.
• W4308396211 hasConcept C203014093 @default.
• W4308396211 hasConcept C23589133 @default.
• W4308396211 hasConcept C2777701055 @default.
• W4308396211 hasConcept C2780427987 @default.
• W4308396211 hasConcept C29390026 @default.
• W4308396211 hasConcept C3875195 @default.
• W4308396211 hasConcept C502942594 @default.
• W4308396211 hasConcept C530470458 @default.
• W4308396211 hasConcept C55493867 @default.
• W4308396211 hasConcept C71924100 @default.
• W4308396211 hasConcept C86803240 @default.
• W4308396211 hasConceptScore W4308396211C121608353 @default.
• W4308396211 hasConceptScore W4308396211C126322002 @default.
• W4308396211 hasConceptScore W4308396211C143998085 @default.
• W4308396211 hasConceptScore W4308396211C147483822 @default.
• W4308396211 hasConceptScore W4308396211C154317977 @default.
• W4308396211 hasConceptScore W4308396211C202751555 @default.
• W4308396211 hasConceptScore W4308396211C203014093 @default.
• W4308396211 hasConceptScore W4308396211C23589133 @default.
• W4308396211 hasConceptScore W4308396211C2777701055 @default.
• W4308396211 hasConceptScore W4308396211C2780427987 @default.
• W4308396211 hasConceptScore W4308396211C29390026 @default.
• W4308396211 hasConceptScore W4308396211C3875195 @default.
• W4308396211 hasConceptScore W4308396211C502942594 @default.
• W4308396211 hasConceptScore W4308396211C530470458 @default.
• W4308396211 hasConceptScore W4308396211C55493867 @default.
• W4308396211 hasConceptScore W4308396211C71924100 @default.
• W4308396211 hasConceptScore W4308396211C86803240 @default.
• W4308396211 hasLocation W43083962111 @default.
• W4308396211 hasOpenAccess W4308396211 @default.
• W4308396211 hasPrimaryLocation W43083962111 @default.
• W4308396211 hasRelatedWork W1974496092 @default.
• W4308396211 hasRelatedWork W2008949385 @default.
• W4308396211 hasRelatedWork W2053177727 @default.
• W4308396211 hasRelatedWork W2083635299 @default.
• W4308396211 hasRelatedWork W2105691222 @default.
• W4308396211 hasRelatedWork W2142210143 @default.
• W4308396211 hasRelatedWork W2266977933 @default.
• W4308396211 hasRelatedWork W2975963069 @default.
• W4308396211 hasRelatedWork W4306834046 @default.
• W4308396211 hasRelatedWork W4308396211 @default.
• W4308396211 isParatext "false" @default.
• W4308396211 isRetracted "false" @default.
• W4308396211 workType "article" @default.